Davy Research

Amryt Pharma (AMYT.L, AMYT LN)

  • 55.7
  • 274.8
  • 54.2

Company Profile

Amryt Pharma is a specialty pharmaceutical company focused on the development and delivery of new treatments for patients with rare and orphan diseases. Amryt has acquired two private companies focussed on treating rare diseases with a specific unmet need. Under the terms of both transactions, Amryt has paid a small amount upfront with the bulk of the proceeds tied to regulatory and revenue-based milestones. This structure serves to limit investor risk as part payment in both cases takes the form of Amryt equity. Amryt has listed on the AIM and ESM exchanges via a reverse takeover.


Major Shareholders%
Cathal Friel11.5
Paul Griffiths4.4
  • AMRYT PHARMA

    Closing Price (p): 20.3

  • RATING 14/09/17

  • PREVIOUS RATING

Analyst(S)

COMPANY DATA

UPCOMING EVENTS

  • There are no upcomming events at present